GlaxoSmithKline (GSK)

Consumer Health (CH) / Rutgers

University School of Pharmacy

Pharmaceutical Industry Fellowship Program 2019

Table of Contents

– Message from Senior

Leadership

– About GlaxoSmithKline (GSK)

– About GSK Consumer

Healthcare (CH)

– Overview of Medical Affairs

Fellowship Position

– Preceptors

– Rutgers, The State University of

New Jersey Component

Message from Senior Leadership

3

Dear Prospective Fellow:

It is a distinct honor and privilege for us at GlaxoSmithKline (GSK) Consumer Healthcare (CH) to sponsor the Rutgers Pharmaceutical Industry Fellowship program. With its long history, the program has prepared several generations of pharmacists for a productive and successful career track within the pharmaceutical industry. From the executive suite to R&D, Drug Information, Clinical Development/Medical Affairs, and Regulatory Affairs, pharmacists are occupying many critical roles across a wide spectrum of the pharmaceutical industry. As one of the world’s largest consumer healthcare companies our mission at GSK is to help people do more, feel better, and live longer. The same aspirations apply to the profession of pharmacy as today’s generation of pharmacists are uniquely qualified to improve health outcomes and the wellbeing of the patients they serve. My previous experience working with Rutgers Fellows in a consumer healthcare company has demonstrated that the pharmacist provides a unique perspective on product development and its eventual introduction into the marketplace.

Over the two-year Fellowship program at GSK Consumer Healthcare, fellows will collaborate with industry Pharm.D. and other professionals on a variety of exciting projects to develop core competencies, including strategic thinking, problem solving, and working in a global matrix environment.

Thank you for your interest in GSK Consumer Healthcare and best wishes for an exciting and fulfilling career as an industry pharmacist.

Sincerely,

Robert J. Chaponis, Pharm.D., RPhHead of Medical Affairs, Americas RegionGlaxoSmithKline Consumer Healthcare

About GlaxoSmithKline (GSK)

At GSK, we want to help people do more, feel better, live longer.Today, there are still millions of people without access to basic healthcare, thousands of diseases without adequate treatments and millions more people who suffer from everyday ailments. At GSK we want to change this.As a global healthcare company, we take on some of the world’s biggest healthcare challenges. By delivering a sustainable business, we provide health benefits to patients and consumers, improved shareholder returns as well as supporting the wider society.We have three world-leading businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products. We are committed to widening access to our products, so more people can benefit, no matter where they live in the world or what they can afford to pay.

4

In 2018, GSK invested £3.9 billion in R&D expenditure across our three businesses. External partnerships and collaborations enable us to develop and access knowledge and increase our understanding in new areas of science.We focus our research across six core areas and are using next-generation technology to develop new approaches to disease management and control.• 44 new medicines in development as of

Q2 2019• 17 oncology asses in the pipeline as of

Q2 2019• 1,500 Our range of partners includes

academic institutions, biotechs, public-private partnerships and pharmaceutical companies

5

Research and Development

Respiratory diseases

HIV and infectious diseases

Vaccines

Immuno-inflammation Oncology Rare diseases

6

Global Science-Led Healthcare Company

GSK’s Consumer Healthcare business develops and markets products in Wellness, Oral health, Nutrition, and Skin health categories. Our seven global power brands – Otrivin, Panadol, Parodontax,

Poligrip, Sensodyne, Theraflu and Voltaren, include some of the most trusted and best-selling brands in the world.

• £7.7bn Sales, -1% AER, +2% CER, 5%

• 25% of Group sales

Consumer HealthcarePharmaceuticals VaccinesGSK’s Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. We have a broad portfolio of innovative and established medicines in respiratory and HIV, in which we are global leaders. We focus our research across respiratory, HIV and infectious diseases, immuno-inflammation, oncology and rare diseases:

• £17.3bn Sales, flat AER, +2% CER

• 56% of Group sales

GSK’s Vaccines business has the broadest portfolio of any company, with vaccines for people of all ages – from babies and adolescents to adults and older people. We deliver over two million vaccine doses per day to people living in over 160 countries.

• £5.9bn Sales, +14% AER, +16% CER

• 19% of Group sales

Our three world-leading businesses research and deliver innovative medicines, vaccines and consumer healthcare products. Performance in 2018 included:• £30.8bn Group sales (+2% AER, +5% CER; 5%)• GSK completed the acquisition of Tesaro, an oncology focused biotech company• GSK Consumer Health and Pfizer Consumer Health Joint venture announced (completed in 2019)• 1st in the Access to Medicine Index since launch in 2008

About GSK Consumer Health (CH)

GSK CH is one of the world’s largest consumer healthcare companies. Our purpose is to help more people around the world to do more, feel better, and live longer with everyday healthcare products. We have a heritage that goes back over 160 years. We own some of the world’s best loved healthcare brands, including Sensodyne®, Theraflu®, Excedrin®, Nicorette® and NicoDerm®CQ®, FLONASE®, and TUMS®. These brands are successful in over 100 countries around the world because they all show our passion for quality, guaranteed by science. They are inspired by the real wants and needs of the millions of people who walk into pharmacies, supermarkets, and purchase sites, as well as go on-line all over the world every day, and choose us first.

Our goal is to build a global Fast Moving Consumer Healthcare (FMCH) company, dedicated to everyday healthcare. We use all of our scientific expertise to deliver quality guarantees that our customers demand, working at the speed and with the genuine consumer understanding the modern world expects.

7

About GSK Consumer Health and Pfizer

Consumer Health Joint Venture

8

GlaxoSmithKline plc (LSE/NYSE: GSK) reached agreement with Pfizer Inc to combine their consumer health businesses into a new world-leading Joint Venture, with combined sales of approximately £9.8 billion ($12.7 billion). GSK will have a majority controlling equity interest of 68% and Pfizer will have an equity interest of 32% in the Joint Venture. The Joint Venture transaction was completed on August 1, 2019.

The new Joint Venture will be well-positioned to deliver stronger sales, cash flow and earnings growth driven by category leading Power Brands, science-based innovation and substantial cost synergies. The combination will bring together two highly complementary portfolios of trusted consumer health brands, including GSK’s Sensodyne, Voltaren and Panadol and Pfizer’s Advil, Centrum and Caltrate. The Joint Venture will be a category leader in Pain Relief, Respiratory, Vitamin and Mineral Supplements, Digestive Health, Skin Health and Therapeutic Oral Health. The Joint Venture will be the global leader in OTC products with a market share of 7.3% ahead of its nearest competitor at 4.1% and have number 1 or 2 market share positions in all key geographies, including the US and China.

Our Values and Standards

Our values guide our day-to-day actions. They reflect our belief that it’s not just what we achieve that counts, it’s also how we achieve it. Therefore, it’s important to keep our values in mind when taking any action or making any decision that relates to your work at GSK.

10

Be patient focused

We focus on the individual, doing what is right for patients and consumers. We work with our partners and customers to improve healthcare and find new medicines and vaccines.

Act with integrity

We are a successful business that acts responsibly with integrity and transparency, living up to the standards that are rightly expected of us.

Demonstrate respect for people

We support and inspire our colleagues to help them be the best they can be and to achieve great things. We listen to the world outside of GSK and use our science and scale to take actions that advance healthcare.

Operate with transparency

We are honest and transparent about what we do, how we do it, and the challenges we face. We are open to challenge, to discussion, and to improving how we work to reflect our values.

Purpose:

– To provide the fellow with the skills and experience needed to launch a successful career within the Pharmaceutical Industry through hands-on experience. The fellow will develop strategic thinking, organizational awareness, leadership skills to support future growth within roles and across their career.

Duration:

– 2 years– June 2020 to June 2022

The Fellow is expected to remain in the Fellowship through the

deadlines identified by Rutgers and to complete the defined GSK CH

and Rutgers requirements to meet the criteria for successful

completion and receive the official Fellowship certification.

11

Overview of Medical Affairs Fellowship Position

Overview of Medical Affairs Fellowship Position

Objectives:

– GSK CH Medical Affairs Fellowship is within GSK CH Research and Development (R&D) and is comprised of the US Medical Affairs (part of the Americas Region Team) and Global Medical Affairs (part of the therapeutic area category teams). The role is located in Warren, NJ.

– Fellows will expand their medical knowledge through active participation on the US Medical Affairs and Global Medical Affairs Team supporting a range of products and projects and learning how they support drug development, launch and life-cycle management.

– The Pharm-D Fellow will work with their preceptor(s) and take on their own products and projects to allow them to develop hands-on experience with the primary responsibilities of a Medical Affairs team member, including:

– Grow capabilities in the Medical Affairs functional area through collaboration with cross-functional R&D and commercial teams

– Create content and provide medical review of advertising and promotional materials for use with external customers, including claims development that can provide a competitive advantage

– Attend regional and national symposiums, presentations, and educational sessions and report key findings

– Lead interactions with key opinion leaders (KOLs) and plan advisory board meetings

– Develop the publication strategy and content of medical publications

– Evaluate innovation opportunities, both internally and externally, and complete the steps to bring in new products

– Support competitive intelligence gathering

– Build medical knowledge and expand opportunities with existing and new products

– Identify new and novel ways to connect with consumers to support their healthcare goals using tools like social media, app-driven education, etc.

– Prepare FAQs, training materials, and response materials for use with sales, the call center team, and other GSK CH functions

– During Year 2 of the Fellowship, there will be an optional rotation based on the fellow’s area of interest and availability. This could include a rotation into another functional area (e.g. Clinical Research, Regulatory Affairs, Drug Safety, Innovation) or Medical Affairs regional role which could be based out of another GSK Global site.

12

Richard Petruschke, PharmD: Lead Preceptor

Director, Digestive Health and Innovation

US Medical Affairs, GSK CH

Richard Petruschke graduated with his Pharm.D. from the University of the Sciences in Philadelphia, PA and completed the Rutgers Pharm.D. Fellowship in 2000 with Hoffmann-La Roche Pharmaceuticals in Regulatory Affairs. He has worked at Hoffman-La Roche Pharmaceuticals (Regulatory Affairs), Merck Pharmaceuticals (Medical Communications), Novartis Pharmaceuticals (Medical Liaison), Novartis Consumer Health (Medical Affairs, Call Center Leadership), and GSK Consumer Health (Call Center Leadership, Medical Affairs and Innovation). Richard was previously a Pharm.D. Medical Affairs Fellow Preceptor at Novartis Consumer Health, and he also precepts Pharm.D. student rotations from Temple University, Western New England University, and Rutgers University. He is active in Scientific and Pharmacy associations, and still practices hospital pharmacy part-time. He will be the primary preceptor for the GSK Consumer Health Fellowship and will oversee the US Medical Affairs component.

13

Stakeholders

Lara Dennie, PharmDDirector, Global Clinical Research

Suzanne Maret , PharmDDirector, Global Clinical Research

14

Rutgers Component

15

Rutgers Component

16

Rutgers Component

17

Rutgers Component

18

Rutgers Component

19

Rutgers Component